Update on pharmacotherapy for treatment of opioid use disorder

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2016-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2016.1244529PMID 27734745
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health

  2017cited by this paper
• Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

  2016cited by this paper
• Alpha₂-adrenergic agonists for the management of opioid withdrawal.

  2016cited by this paper
• Predictors of non-use of illicit heroin in opioid injection maintenance treatment of long-term heroin dependence.

  2015cited by this paper
• Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

  2015cited by this paper
• Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged ≤30 Years — Kentucky, Tennessee, Virginia, and West Virginia, 2006–2012

  2015cited by this paper
• Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.

  2015cited by this paper
• Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.

  2015cited by this paper
• Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.

  2015cited by this paper
• Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study.

  2015cited by this paper
• Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

  2015cited by this paper
• Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.

  2015cited by this paper
• Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder.

  2015cited by this paper
• Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

  2015cited by this paper
• Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX)

  2015cited by this paper
• Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial.

  2015cited by this paper
• Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.

  2014cited by this paper
• Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians.

  2014cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2014cited by this paper
• Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial).

  2014cited by this paper
• Alpha2-adrenergic agonists for the management of opioid withdrawal.

  2014cited by this paper
• A mosque-based methadone maintenance treatment strategy: implementation and pilot results.

  2014cited by this paper
• The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users.

  2014cited by this paper
• Methadone Induction in Primary Care for Opioid Dependence: A Pragmatic Randomized Trial (ANRS Methaville)

  2014cited by this paper
• The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol

  2014cited by this paper
• Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011.

  2014cited by this paper
• Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

  2014cited by this paper
• Does training in motivational interviewing for community pharmacists improve outcomes for methadone patients? A cluster randomised controlled trial

  2014cited by this paper
• Pharmacological strategies for detoxification

  2014cited by this paper
• An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone.

  2014cited by this paper
• Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.

  2014cited by this paper
• The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

  2013cited by this paper
• An Evidence-Based Systematic Review of Kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration

  2013cited by this paper
• Methadone at tapered doses for the management of opioid withdrawal.

  2013cited by this paper
• Treatment expectations and satisfaction of treatment-refractory opioid-dependent patients in RIOTT, the Randomised Injectable Opiate Treatment Trial, the UK's first supervised injectable maintenance clinics.

  2013cited by this paper
• A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial.

  2013cited by this paper
• An intervention targeting service providers and clients for methadone maintenance treatment in China: a cluster-randomized trial.

  2013cited by this paper
• A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence.

  2013cited by this paper
• A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans.

  2013cited by this paper
• Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

  2013cited by this paper
• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• A Comparison of Buprenorphine Taper Outcomes Between Prescription Opioid and Heroin Users

  2013cited by this paper
• Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade?

  2013cited by this paper
• Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention.

  2013cited by this paper
• Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.

  2013cited by this paper
• Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.

  2013cited by this paper
• Maintenance agonist treatments for opiate-dependent pregnant women.

  2013cited by this paper
• Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines

  2012cited by this paper
• Trazodone for sleep disturbance during methadone maintenance: a double-blind, placebo-controlled trial.

  2012cited by this paper
• Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates.

  2012cited by this paper
• Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.

  2012cited by this paper
• Postprison release HIV-risk behaviors in a randomized trial of methadone treatment for prisoners.

  2012cited by this paper
• Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial.

  2012cited by this paper
• Maternal Opioid Treatment: Human Experimental Research (MOTHER) Study: maternal, fetal and neonatal outcomes from secondary analyses.

  2012cited by this paper
• Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

  2012cited by this paper
• Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course.

  2012cited by this paper
• A Randomized Trial of Methadone Initiation Prior to Release from Incarceration

  2012cited by this paper
• Clonidine Improved Laboratory-Measured Decision-Making Performance in Abstinent Heroin Addicts

  2012cited by this paper
• Oral naltrexone maintenance treatment for opioid dependence.

  2011cited by this paper
• Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.

  2011cited by this paper
• Heroin maintenance for chronic heroin-dependent individuals.

  2011cited by this paper
• Hepatitis C virus infection among adolescents and young adults:Massachusetts, 2002-2009.

  2011cited by this paper
• QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone‐treated patients in France

  2011cited by this paper
• Oral naltrexone maintenance treatment for opioid dependence.

  2011cited by this paper
• The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

  2011cited by this paper
• Induction of Opioid‐Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone Soluble‐Films

  2011cited by this paper
• Barriers to Use of Pharmacotherapy for Addiction Disorders and How to Overcome Them

  2011cited by this paper
• Interim methadone treatment compared to standard methadone treatment: 4-month findings.

  2011cited by this paper
• Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes.

  2011cited by this paper
• Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study

  2011cited by this paper
• Lofexidine, an α2-Receptor Agonist for Opioid Detoxification

  2010cited by this paper
• Provision of Ancillary Medications During Buprenorphine Detoxification Does Not Improve Treatment Outcomes

  2010cited by this paper
• Nocturnal sleep architecture disturbances in early methadone treatment patients.

  2010cited by this paper
• Challenges to antagonist blockade during sustained-release naltrexone treatment.

  2010cited by this paper
• Opiate-Addicted Parents in Methadone Treatment: Long-Term Recovery, Health, and Family Relationships

  2010cited by this paper
• Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available

  2010cited by this paper
• Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

  2010cited by this paper
• Neonatal abstinence syndrome after methadone or buprenorphine exposure.

  2010cited by this paper
• Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial.

  2010cited by this paper
• Interim methadone treatment: impact on arrests.

  2009cited by this paper
• Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial

  2009cited by this paper
• Brief buprenorphine detoxification for the treatment of prescription opioid dependence: a pilot study.

  2009cited by this paper
• Early outcomes following low dose naltrexone enhancement of opioid detoxification.

  2009cited by this paper
• Alpha2-adrenergic agonists for the management of opioid withdrawal.

  2009cited by this paper
• Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.

  2009cited by this paper
• Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

  2009cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2009cited by this paper
• Buprenorphine tapering schedule and illicit opioid use.

  2009cited by this paper
• Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years.

  2008cited by this paper
• Maintenance agonist treatments for opiate dependent pregnant women.

  2008cited by this paper
• Opioid complications and side effects.

  2008cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2008cited by this paper
• Clinical efficacy of citalopram alone or augmented with bupropion in methadone-stabilized patients.

  2007cited by this paper
• Factors for Employment: A Case-Control Study of Fully Employed and Unemployed Heroin Users

  2007cited by this paper
• Pharmacologic treatments for opioid dependence: detoxification and maintenance options

  2007cited by this paper
• Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence.

  2006cited by this paper
• Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital.

  2006cited by this paper
• A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network.

  2005cited by this paper
• Illicit use of opioid analgesics by high school seniors.

  2005cited by this paper
• Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

  2005cited by this paper

• An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications

  2025cites this paper
• Cardiac Assessment of Individuals with Opioid Use Disorder under Methadone Treatment

  2025cites this paper
• Medicine vs. Myth: Exploring the Therapeutic Potential of Cannabis for Opioid Use Disorder and Pain

  2025cites this paper
• Healthcare provider perspectives on the facilitators, barriers and unexplored opportunities to support the recovery of clients on medications for opioid use disorder in Kenya

  2024cites this paper
• Informing evidence-based medicine for opioid use disorder using pharmacoeconomic studies

  2024cites this paper
• Telehealth Utilization for Opioid Use Disorder: A Nationwide Analysis Before and After the COVID-19 Public Health Emergency Declaration

  2024cites this paper
• Development and Evaluation of a Digital App for Patient Self-Management of Opioid Use Disorder: Usability, Acceptability, and Utility Study

  2024cites this paper
• Association Between Variables and Transitions Among No Opioid Use, Opioid Use, and Subsequent Dropout Among Participants on Methadone Treatment: A Retrospective Study Utilizing a Multistate Model

  2024cites this paper
• A Step Toward Equity: Evidence-Based Policy for Access to Medications for Healthcare Workers With Opioid Use Disorder

  2023cites this paper
• Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication

  2023cites this paper
• Development of a vaccine against the synthetic opioid U-47700

  2023cites this paper
• Acupuncture for protracted opioid abstinence syndrome: study protocol for a systematic review and meta-analysis

  2023cites this paper
• Feasibility, acceptability and preliminary efficacy of a cognitive behavior therapy text-message intervention among individuals with opioid use disorder in Kenya: a randomized feasibility trial

  2023cites this paper
• Relapses in Illicit Drug Use Among Probationers: Results in a Risk Group of Public Health Services in Bavaria

  2023cites this paper
• Glymphatic-System Function Is Associated with Addiction and Relapse in Heroin Dependents Undergoing Methadone Maintenance Treatment

  2023cites this paper
• Association of Medication Treatment for Opioid Use Disorder With Suicide Mortality.

  2022cites this paper
• Exploring the experiences of clients receiving opioid use disorder treatment at a methadone clinic in Kenya: a qualitative study

  2022cites this paper
• Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy

  2022cites this paper
• Perceptions of E-cigarettes among adults in treatment for opioid use disorder

  2022cites this paper
• Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials.

  2022cites this paper
• Ligand-Free Signaling of G-Protein-Coupled Receptors: Relevance to μ Opioid Receptors in Analgesia and Addiction

  2022influential citation
• Mobile phone ownership, digital technology use and acceptability of digital interventions among individuals on opioid use disorder treatment in Kenya

  2022cites this paper
• Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor

  2022cites this paper
• Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients

  2021cites this paper
• Pharmacogenetic study of methadone treatment for heroin addiction: associations between drug-metabolizing gene polymorphisms and treatment efficacy

  2021cites this paper
• Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids.

  2021cites this paper
• Opioids Disrupt Sleep and Wakefulness in C57BL/6J mice

  2021cites this paper
• Naltrexone Implant for Opioid Use Disorder

  2021cites this paper
• Understanding the Barriers to Prescribing Buprenorphine in Massachusetts

  2021cites this paper
• The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya

  2021cites this paper
• Comparative study of dezocine, pentazocine and tapentadol on antinociception and physical dependence.

  2021cites this paper
• Learning From the Lived Experiences of People With Opioid Use Disorder

  2021cites this paper
• Viral vector-mediated gene therapy for opioid use disorders.

  2021cites this paper
• Facial and bilateral lower extremity edema due to drug-drug interactions in a patient with hepatitis C virus infection and benign prostate hypertrophy: A case report

  2020cites this paper
• Drug Legalization and Decriminalization Beliefs Among Substance-using and Nonusing Individuals.

  2020cites this paper
• Intranasal Insulin: a Treatment Strategy for Addiction

  2020cites this paper
• Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: Current understanding and approaches to management

  2020cites this paper
• Tapering opioids: a comprehensive qualitative review.

  2020cites this paper
• Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation

  2020cites this paper
• Evaluation of the Reinforcing Strength of Phendimetrazine Using a Progressive-Ratio Schedule of Reinforcement in Rhesus Monkeys

  2020cites this paper
• Non-invasive brain stimulation modalities for the treatment and prevention of opioid use disorder: a systematic review of the literature

  2020cites this paper
• A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.

  2020cites this paper
• Treatment of Opioid Use Disorder in the Elderly

  2020cites this paper
• Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone

  2020cites this paper
• Cannabis Use Among Patients Attending A Methadone Maintenance Treatment Clinic In Nairobi, Kenya

  2020cites this paper
• EFEK IMUNOLOGI PADA PENGGUNAAN OPIOID AKUT DAN KRONIS

  2020cites this paper
• Traditional Chinese Medicine-Guided Dietary Intervention for Male Youth Undergoing Drug Detoxification: A Randomized Controlled Trial

  2019cites this paper
• Do All Opioid Drugs Share the Same Immunomodulatory Properties? A Review From Animal and Human Studies

  2019cites this paper
• Efficacy and safety of Sophora alopecuroides var. alopecuroides seed extract for opioid detoxification: A randomized, double‐blind, and placebo‐controlled clinical trial

  2019cites this paper
• Adjunctive memantine for opioid use disorder treatment: A systematic review.

  2019cites this paper
• Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users.

  2019cites this paper
• Medication-Assisted Treatment for Opioid-Use Disorder.

  2019cites this paper
• Escalated oxycodone self-administration causes differential striatal mRNA expression of FGFs and IEGs following abstinence-associated incubation of oxycodone craving.

  2019cites this paper
• Stress and opioid use disorder: A systematic review.

  2019cites this paper
• Innovative pharmakologische Ansätze zur Behandlung von Suchterkrankungen

  2019cites this paper
• Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons

  2019cites this paper
• Current Understanding of the Neurobiology of Opioid Use Disorder: an Overview

  2019cites this paper
• Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment

  2019influential citation
• Opioid receptors: drivers to addiction?

  2018cites this paper
• Best practices across the continuum of care for the treatment of opioid use disorder.

  2018cites this paper
• Liver damage indices as a tool for modifying methadone maintenance treatment: a cross-sectional study

  2018cites this paper
• Evidence-based strategies for preventing opioid overdose : what’s working in the United States : an introduction for public heath, law enforcement, local organizations, and others striving to serve their community

  2018cites this paper
• Pharmacological and Behavioral Treatment of Opioid Use Disorder

  2018cites this paper
• Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges.

  2018cites this paper
• Pharmacological Research as a Key Component in Mitigating the Opioid Overdose Crisis.

  2018cites this paper
• Strategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United States

  2018cites this paper
• How treatment improvement in ADHD and cocaine dependence are related to one another: A secondary analysis.

  2018cites this paper
• Attentional bias in opioid users: A systematic review and meta-analysis.

  2018cites this paper
• Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis

  2018cites this paper
• The effectiveness, safety and feasibility of extended-release naltrexone in treatment of opioid dependence: A 12-month clinical study

  2018cites this paper
• 2017 update on pain management in patients with chronic kidney disease

  2017cites this paper
• Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women

  2017cites this paper
• Minding the brain: the role of pharmacotherapy in substance-use disorder treatment

  2017cites this paper
• America’s Opioid Epidemic: Supply and Demand Considerations

  2017cites this paper
• W 2017 update on pain management in patients with chronic kidney disease

  2017cites this paper